Recently, next generation sequencing has revealed additional recurrent alterations in CLL targeting the NOTCH1, SF3B1, and BIRC3 genes. NOTCH1, SF3B1, and BIRC3 lesions provide new insights on the mechanisms of leukemogenesis, tumor progression and chemoresistance CLL.
O dear, what a complicated article. It seems to explain different ways CLL may "progress", but nothing much to help actual sufferers.
This highly scientific research, trying to explain what goes wrong with CLL DNA, and the process of how CLL attacks the body.
It could lead to a breakthrough in time, new treatments or a better understanding of CLL, perhaps answer some questions and pose a whole new series.
Clinically it has no applications.
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patientsProf Dr Susan O'Brien - Lessons Learned From the CAPTIVATE Trial of Ibrutinib Plus Venetoclax in CLLOverview of Autoimmune Cytopenias in CLLVenR in Relapsed CLL: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from MURANO 3 study
CLL and skin issues/genetic markers
